Non-Small Cell Lung Cancer New Reference: Neoadjuvant Nivolumab for NSCLC Ulas D. Bayraktar, MD 2025-09-08
Non-Small Cell Lung Cancer New Reference: Adagrasib for kRAS Mutated NSCLC Ulas D. Bayraktar, MD 2025-09-08
Non-Small Cell Lung Cancer New Indication: Neoadjuvant Osimertinib with/without Chemo for NSCLC Ulas D. Bayraktar, MD 2025-09-08
Non-Small Cell Lung Cancer New Drug: Telisotuzumab vedotin for cMET Amplified NSCLC Ulas D. Bayraktar, MD 2025-06-09
Non-Small Cell Lung Cancer New Reference: Taletrectinib for ROS1+ NSCLC Ulas D. Bayraktar, MD 2025-06-02
Non-Small Cell Lung Cancer New Reference: Maintenance Atezolizumab for Stage IB-IIIA NSCLC Ulas D. Bayraktar, MD 2025-06-02
Non-Small Cell Lung Cancer New Reference: Zongertinib for her2 Mutated NSCLC Ulas D. Bayraktar, MD 2025-05-05
Non-Small Cell Lung Cancer New Reference: Afatinib for NSCLC with Uncommon EGFR Mutations Ulas D. Bayraktar, MD 2025-04-22
Non-Small Cell Lung Cancer New Indication: Nivolumab – Ipilimumab for Neoadjuvant NSCLC Ulas D. Bayraktar, MD 2025-04-22
Non-Small Cell Lung Cancer New Reference: Taletrectinib for ROS1-Positive NSCLC Ulas D. Bayraktar, MD 2025-04-22
